Therapeutic approaches to protein-misfolding diseases

Several sporadic and genetic diseases are caused by protein misfolding. These include cystic fibrosis and other devastating diseases of childhood as well as Alzheimer's, Parkinson's and other debilitating maladies of the elderly. A unified view of the molecular and cellular pathogenesis of these conditions has led to the search for chemical chaperones that can slow, arrest or revert disease progression. Molecules are now emerging that link our biophysical insights with our therapeutic aspirations.

[1]  W. Welch,et al.  Manipulating the Folding Pathway of ΔF508 CFTR Using Chemical Chaperones , 2002 .

[2]  J. Kelly,et al.  Prevention of Transthyretin Amyloid Disease by Changing Protein Misfolding Energetics , 2003, Science.

[3]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[4]  Jian‐Qiang Fan A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity. , 2003, Trends in pharmacological sciences.

[5]  P. Zeitlin,et al.  Therapeutic approaches to repair defects in deltaF508 CFTR folding and cellular targeting. , 2002, Advanced drug delivery reviews.

[6]  Pauline M. Rudd,et al.  Antibodies inhibit prion propagation and clear cell cultures of prion infectivity , 2001, Nature.

[7]  S. Angers,et al.  Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. , 2000, The Journal of clinical investigation.

[8]  M. Bouvier,et al.  Ligands act as pharmacological chaperones and increase the efficiency of δ opioid receptor maturation , 2002, The EMBO journal.

[9]  P. Lansbury,et al.  Amyloid fibrillogenesis: themes and variations. , 2000, Current opinion in structural biology.

[10]  J. Collinge,et al.  Monoclonal antibodies inhibit prion replication and delay the development of prion disease , 2003, Nature.

[11]  James C. Sacchettini,et al.  Therapeutic strategies for human amyloid diseases , 2002, Nature Reviews Drug Discovery.

[12]  M. Wolfe Secretase as a target for Alzheimer's disease. , 2002, Current topics in medicinal chemistry.

[13]  J. Swatton,et al.  Inhibition of fibril formation in beta-amyloid peptide by a novel series of benzofurans. , 1999, The Biochemical journal.

[14]  D. Lomas,et al.  Alpha1-antitrypsin deficiency--a model for conformational diseases. , 2002, The New England journal of medicine.

[15]  C. Lemere,et al.  The generation and characterization of potentially therapeutic Abeta antibodies in mice: differences according to strain and immunization protocol. , 2002, Vaccine.

[16]  D. Perlmutter,et al.  Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Satoshi Ishii,et al.  Accelerated transport and maturation of lysosomal α–galactosidase A in Fabry lymphoblasts by an enzyme inhibitor , 1999, Nature Medicine.

[18]  P. Lansbury,et al.  Seeding “one-dimensional crystallization” of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie? , 1993, Cell.

[19]  J. Kelly,et al.  Support for the multigenic hypothesis of amyloidosis: The binding stoichiometry of retinol-binding protein, vitamin A, and thyroid hormone influences transthyretin amyloidogenicity in vitro , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Chao Quan,et al.  Benzoflavone activators of the cystic fibrosis transmembrane conductance regulator: towards a pharmacophore model for the nucleotide-binding domain. , 2003, Bioorganic & medicinal chemistry.

[21]  Robert J. Desnick,et al.  Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. , 2001, The New England journal of medicine.

[22]  T. Morgan,et al.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[23]  J. Kelly,et al.  Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[24]  J. Kelly,et al.  Transthyretin slowly exchanges subunits under physiological conditions: A convenient chromatographic method to study subunit exchange in oligomeric proteins , 2001, Protein science : a publication of the Protein Society.

[25]  F. Itoh,et al.  The Antisense Approach in Amyloid Light Chain Amyloidosis: Identification of Monoclonal Ig and Inhibition of Its Production by Antisense Oligonucleotides in In Vitro and In Vivo Models1 , 2002, The Journal of Immunology.

[26]  Carl W. Cotman,et al.  Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.

[27]  F. Heppner,et al.  Prevention of Scrapie Pathogenesis by Transgenic Expression of Anti-Prion Protein Antibodies , 2001, Science.

[28]  J. Kelly,et al.  Alternative conformations of amyloidogenic proteins govern their behavior. , 1996, Current opinion in structural biology.

[29]  B. Solomon Anti-aggregating antibodies, a new approach towards treatment of conformational diseases. , 2002, Current medicinal chemistry.

[30]  S. Weggen,et al.  Nonsteroidal antiinflammatory drugs as therapeutic agents for Alzheimer's disease , 2002 .

[31]  Fred E. Cohen,et al.  Folding of Prion Protein to Its Native α-Helical Conformation Is under Kinetic Control* , 2001, The Journal of Biological Chemistry.

[32]  F. Cohen,et al.  Potent inhibition of scrapie prion replication in cultured cells by bis-acridines , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[33]  J. Kelly,et al.  Amyloid as a natural product , 2003, The Journal of cell biology.

[34]  S. Kaushal,et al.  Pharmacological Chaperone-mediated in Vivo Folding and Stabilization of the P23H-opsin Mutant Associated with Autosomal Dominant Retinitis Pigmentosa* , 2003, The Journal of Biological Chemistry.

[35]  Shuxia Zhao,et al.  The Binding Site for Channel Blockers That Rescue Misprocessed Human Long QT Syndrome Type 2 ether-a-gogo-related Gene (HERG) Mutations* , 2002, The Journal of Biological Chemistry.

[36]  C. Anfinsen Principles that govern the folding of protein chains. , 1973, Science.

[37]  F E Cohen,et al.  Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[38]  R. Vassar,et al.  β-Secretase (BACE) as a drug target for alzheimer’s disease , 2002 .

[39]  Rw Carrell,et al.  Mechanisms of disease - Alpha(1)-antitrypsin deficiency - A model for conformational diseases , 2002 .

[40]  M. Findeis,et al.  Peptide inhibitors of beta amyloid aggregation. , 2002, Current topics in medicinal chemistry.

[41]  C. Holmes,et al.  Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report , 2003, Nature Medicine.

[42]  A. Fersht,et al.  Mechanism of rescue of common p53 cancer mutations by second‐site suppressor mutations , 2000, The EMBO journal.

[43]  J. Greer,et al.  Structure-Activity Relations of Successful Pharmacologic Chaperones for Rescue of Naturally Occurring and Manufactured Mutants of the Gonadotropin-Releasing Hormone Receptor , 2003, Journal of Pharmacology and Experimental Therapeutics.

[44]  K. Fiebig,et al.  Antimalarial drug quinacrine binds to C-terminal helix of cellular prion protein. , 2003, Journal of medicinal chemistry.

[45]  D. Westaway,et al.  Assembly of Alzheimer's amyloid-beta fibrils and approaches for therapeutic intervention. , 2001, Amyloid: Journal of Protein Folding Disorders.

[46]  Christopher M. Dobson,et al.  Amyloid fibrils from muscle myoglobin , 2001, Nature.

[47]  Ernest Beutler,et al.  Chemical chaperones increase the cellular activity of N370S β-glucosidase: A therapeutic strategy for Gaucher disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[48]  F. Cohen,et al.  Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein , 1995, Cell.

[49]  J. Kelly,et al.  Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. , 1992, Biochemistry.